NCT01760109

Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) for Treatment of Respiratory and Urinary System Infection

Phase IV Study on Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) for Treatment of Respiratory and Urinary System Infection

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 2,000 (actual)
• Sponsor: Xiangbei Welman Pharmaceutical Co., Ltd · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

In the proposed study, the investigators plan to evaluate the efficacy and safety of Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) for the treatment of respiratory and urinary tract acute bacterial infection.

Detailed description

Piperacillin sodium and sulbactam sodium for injection (2:1)plays a therapeutic role by the former inhibiting bacterial cell wall synthesis，the latter making irreversible competitive inhibition of β-lactamase.The antimicrobial effect of Piperacillin can be enhanced by the two combined. The compound specifically aims to the mechanism of bacterial resistance, extending the life of Piperacillin in the treatment-resistant pathogen infections.

Conditions

• Respiratory Tract Infections
• Urinary Tract Infections

Interventions

Type	Name	Description
DRUG	Piperacillin Sodium and Sulbactam Sodium	1.5-3.0g,iv,bid 7-14 days serious infections 6.0-12.0g,iv,tid for 7-14 days

Timeline

• Start date: 2011-07-01
• Primary completion: 2016-06-01
• Completion: 2016-06-01
• First posted: 2013-01-03
• Last updated: 2019-07-08

Locations

1 site across 1 country: China